From Bench-to-Bedside: A Review of Clinical Trials in Drug Discovery and Development

Abstract

Clinical trials bridge basic research and clinical application, serving as essential steps in drug development. This review examines clinical trial phases (Phase I [safety assessment], Phase II [efficacy evaluation], Phase III [large-scale validation], and Phase IV [post-marketing surveillance]), highlighting the distinct characteristics and interconnections. Major challenges are identified, including ethical compliance, participant recruitment, and ensuring diversity and representativeness in trial populations, while proposing evidence-based mitigation strategies. To address these challenges, innovative technologies, such as artificial intelligence, big data analytics, and digital health tools, are transforming trial design and implementation, enhancing efficiency and data quality. Looking forward, the review explores how emerging therapies, including gene therapy and immunotherapy, are reshaping trial design requirements and emphasizes the growing importance of regulatory harmonization and global collaboration. Clinical trials remain central to advancing innovative drug development and improving patient outcomes.

Keywords

Artificial intelligence / clinical trials / drug development / personalized medicine / real-world evidence / regulatory compliance

References

[1] Van de Sande B, Lee JS, Mutasa-Gottgens E, Naughton B, Bacon W, et al. Applications of single-cell RNA sequencing in drug discovery and development. Nat Rev Drug Discov 2023; 22(6): 496-520. [PMID: 37117846 DOI: 10.1038/s41573-023-00688-4]

[2] Sadybekov AV, Katritch V. Computational approaches streamlining drug discovery. Nature 2023; 616(7958): 673-85. [PMID: 37100941 DOI: 10.1038/s41586-023-05905-z]

[3] von Delft A, Hall MD, Kwong AD, Purcell LA, Saikatendu KS, et al. Accelerating antiviral drug discovery: lessons from COVID-19. Nat Rev Drug Discov 2023; 22(7): 585-603. [PMID: 37173515 DOI: 10.1038/s41573-023-00692-8]

[4] Piantadosi S. Clinical trials: a methodologic perspective. 4th ed. Hoboken, NJ: John Wiley & Sons; 2024.

[5] Teicher BA, Andrews PA. Anticancer drug development guide: preclinical screening, clinical trials, and approval. Humana Totowa, NJ: Springer Science & Business Media; 2004. [DOI: 10.1007/978-1-59259-739-0]

[6] Blass BE. Basic principles of drug discovery and development. Elsevier; 2015.

[7] Herrling PL. The drug discovery process. In: Herrling PL, Matter A, Rudin M, editors. Imaging in drug discovery and early clinical trials. Progress in Drug Research. Birkhäuser Basel; 2005. pp. 1-14. [DOI: 10.1007/3-7643-7426-8_1]

[8] Abbasi N, Fnu N, Zeb S. AI in healthcare: using cutting-edge technologies to revolutionize vaccine development and distribution. JURIHUM 2023; 1(1): 17-29.

[9] Zhang J, Zhang Y, Wang J, Xia Y, Zhang J, et al. Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies. Signal Transduct Target Ther 2024; 9(1): 211. [PMID: 39174535 DOI: 10.1038/s41392-024-01911-3]

[10] Bannigan P, Hickman RJ, Aspuru-Guzik A, Allen C. The dawn of a new pharmaceutical epoch: can ai and robotics reshape drug formulation? Adv Healthc Mater 2024; 13(29): 2401312. [PMID: 39155417 DOI: 10.1002/adhm.202401312]

[11] Salvagno M, DE Cassai A, Zorzi S, Zaccarelli M, Pasetto M, et al. The state of artificial intelligence in medical research: a survey of corresponding authors from top medical journals. PLoS One 2024; 19(8): e0309208. [PMID: 39178224 DOI: 10.1371/journal.pone.0309208]

[12] Harrer S, Shah P, Antony B, Hu J. Artificial intelligence for clinical trial design. Trends Pharmacol Sci 2019; 40(8): 577-91. [PMID: 31326235 DOI: 10.1016/j.tips.2019.05.005]

[13] Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov 2019; 18(6): 463-77. [PMID: 30976107 DOI: 10.1038/s41573-019-0024-5]

[14] Coravos A, Khozin S, Mandl KD. Developing and adopting safe and effective digital biomarkers to improve patient outcomes. NPJ Digit Med 2019; 2(1): 14. [PMID: 30868107 DOI: 10.1038/s41746-019-0090-4]

[15] Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, et al. Real-world evidence - what is it and what can it tell us? N Engl J Med 2016; 375(23): 2293-7.

[16] Dunbar CE, High KA, Joung JK, Kohn DB, Ozawa K, et al. Gene therapy comes of age. Science 2018; 359(6372): eaan4672. [PMID: 29326244 DOI: 10.1126/science.aan4672]

[17] June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC . CAR T cell immunotherapy for human cancer. Science 2018; 359(6382): 1361-5. [PMID: 29567707 DOI: 10.1126/science.aar6711]

[18] Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med 2017; 377(1): 62-70. [PMID: 28679092 DOI: 10.1056/NEJMra1510062]

[19] Hwang TJ, Darrow JJ, Kesselheim AS. The FDA’s expedited programs and clinical development times for novel therapeutics, 2012-2016. JAMA 2017; 318(21): 2137-8. [PMID: 29209711 DOI: 10.1001/jama.2017.14896]

[20] Darrow JJ, Avorn J, Kesselheim AS. FDA approval and regulation of pharmaceuticals, 1983-2018. JAMA 2020; 323(2): 164-76. [PMID: 31935033 DOI: 10.1001/jama.2019.20288]

[21] Chakraborty C, Bhattacharya M, Lee SS. Artificial intelligence enabled ChatGPT and large language models in drug target discovery, drug discovery, and development. Mol Ther Nucleic Acids 2023; 33: 866-8. [PMID: 37680991 DOI: 10.1016/j.omtn.2023.08.009]

[22] Trajanoska K, Bhérer C, Taliun D, Zhou S, Richards JB, et al. From target discovery to clinical drug development with human genetics. Nature 2023; 620(7975): 737-45. [PMID: 37612393 DOI: 10.1038/s41586-023-06388-8]

[23] Parvatikar PP, Patil S, Khaparkhuntikar K, Patil S, Singh PK, et al. Artificial intelligence: machine learning approach for screening large database and drug discovery. Antiviral Res 2023; 220: 105740. [PMID: 37935248 DOI: 10.1016/j.antiviral.2023.105740]

[24] Pun FW, Ozerov IV, Zhavoronkov A. AI-powered therapeutic target discovery. Trends Pharmacol Sci 2023; 44(9): 561-72. [PMID: 37479540 DOI: 10.1016/j.tips.2023.06.010]

[25] Smith AJ. New horizons in therapeutic antibody discovery: opportunities and challenges versus small-molecule therapeutics. J Biomol Screen 2015; 20(4): 437-53. [PMID: 25512329 DOI: 10.1177/1087057114562544]

[26] Kell DB. Finding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening and knowledge of transporters: where drug discovery went wrong and how to fix it. FEBS J 2013; 280(23): 5957-80. [PMID: 23552054 DOI: 10.1111/febs.12268]

[27] Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery. Br J Pharmacol 2011; 162(6): 1239-49. [PMID: 21091654 DOI: 10.1111/j.1476-5381.2010.01127.x]

[28] Mittal P, Chopra H, Kaur KP, Gautam RK. New drug discovery pipeline. In: Gautam RK, Kamal MA, Mittal P, editors. Computational approaches in drug discovery, development and systems pharmacology. Elsevier; 2023. pp. 197-222. [DOI: 10.1016/B978-0-323-99137-7.00003-4]

[29] Udegbe FC, Ebulue OR, Ebulue CC, Ekesiobi CS. Machine learning in drug discovery: a critical review of applications and challenges. Comput Sci IT Res J 2024; 5(4): 892-902. [DOI: 10.51594/csitrj.v5i4.1048]

[30] Chawla G, Pradhan T. 2 Lead-hit-based methods for drug design and ligand identification. In: Computational drug discovery: molecular simulation for medicinal chemistry. 2024. pp. 23.

[31] Negi S, Kumar S, Singh A. Preclinical in vivo drug development studies: limitations, model organisms, and techniques. In: Rajput VS, Runthala A, editiors. Drugs and a methodological compendium: from bench to bedside. Singapore: Springer; 2023. pp. 149-71. [DOI: 10.1007/978-981-19-7952-1_6]

[32] Harvey WD. Species selection for pharmaceutical toxicity studies. In: Hock FJ, Pugsley MK, editors. Drug discovery and evaluation: safety and pharmacokinetic assays. Cham: Springer; 2024. pp. 2271-301. [DOI: 10.1007/978-3-031-35529-5_133]

[33] Srivastava AK, Negi G. Role of nonclinical programs in drug development. In: Jagadeesh G, Balakumar P, Senatore F, editors. The quintessence of basic and clinical research and scientific publishing. Singapore: Springer; 2023. pp. 579-93. [DOI: 10.1007/978-981-99-1284-1_35]

[34] Guo H, Xu X, Zhang J, Du Y, Yang X, et al. The pivotal role of preclinical animal models in anti-cancer drug discovery and personalized cancer therapy strategies. Pharmaceuticals (Basel) 2024; 17(8): 1048. [PMID: 39204153 DOI: 10.3390/ph17081048]

[35] Bode G, Starck-Lantova P, Kramer PJ. Future of regulatory safety assessment. How to improve drug development? Focus on preclinical strategies. In: Hock FJ, Pugsley MK, editors. Drug discovery and evaluation: safety and pharmacokinetic assays. Cham: Springer; 2023. pp. 1-26. [DOI: 10.1007/978-3-030-73317-9_142-1]

[36] Infante JR, Patnaik A, Verschraegen CF, Olszanski AJ, Shaheen M, et al. Two phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer. Cancer Chemother Pharmacol 2017; 79(2): 315-26. [PMID: 28097385 DOI: 10.1007/s00280-016-3205-5]

[37] Zonder JA, Mohrbacher AF, Singhal S, Van Rhee F, Bensinger WI, et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 2012; 120(3): 552-9. [PMID: 22184404 DOI: 10.1182/blood-2011-06-360552]

[38] Philip G, Pedinoff A, Vandormael K, Tymofyeyev Y, Smugar SS, et al. A phase I randomized, placebo-controlled, dose-exploration study of single-dose inhaled montelukast in patients with chronic asthma. J Asthma 2010; 47(10): 1078-84. [PMID: 20936994 DOI: 10.3109/02770903.2010.520100]

[39] Li T, LoRusso P, Maitland ML, Ou SHI, Bahceci E, et al. First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors. J Hematol Oncol 2016; 9: 23.

[40] Paz-Ares L, Spigel DR, Chen Y, Jove M, Juan-Vidal O, et al. RESILIENT part 1: a phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer. Cancer 2022; 128(9): 1801-11. [PMID: 35195913 DOI: 10.1002/cncr.34123]

[41] Skinner JB. Early exploration of safety and efficacy. Drug Inf J 1990; 24(2): 325-39. [DOI: 10.1177/009286159002400207]

[42] Korn EL, Moscow JA, Freidlin B. Dose optimization during drug development: whether and when to optimize. J Natl Cancer Inst 2023; 115(5): 492-7. [PMID: 36534891 DOI: 10.1093/jnci/djac232]

[43] Dixon BP, Greenbaum LA, Huang L, Rajan S, Ke C, et al. Clinical safety and efficacy of pegcetacoplan in a phase 2 study of patients with C3 glomerulopathy and other complement-mediated glomerular diseases. Kidney Int Rep 2023; 8(11): 2284-93. [PMID: 38025230 DOI: 10.1016/j.ekir.2023.08.033]

[44] Chen C. To go or not to go in phase 2/3 oncology trials, a critical question with a unified answer. Contemp Clin Trials 2023; 128: 107146. [PMID: 36921690 DOI: 10.1016/j.cct.2023.107146]

[45] Jiang L, Yuan Y. Seamless phase II/III design: a useful strategy to reduce the sample size for dose optimization. J Natl Cancer Inst 2023; 115(9): 1092-8.

[46] Brody T. Clinical trials: study design, endpoints and biomarkers, drug safety, and FDA and ICH guidelines. Amsterdam: Elsevier/Academic Press; 2016. pp. 863.

[47] Hwang TJ, Carpenter D, Lauffenburger JC, Wang B, Franklin JM, et al. Failure of investigational drugs in late-stage clinical development and publication of trial results. JAMA Intern Med 2016; 176(12): 1826-33. [PMID: 27723879 DOI: 10.1001/jamainternmed.2016.6008]

[48] Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, et al. Clinical trials and late-stage drug development for Alzheimer’s disease: an appraisal from 1984 to 2014. J Intern Med 2014; 275(3): 251-83. [PMID: 24605808 DOI: 10.1111/joim.12191]

[49] Umscheid CA, Margolis DJ, Grossman CE. Key concepts of clinical trials: a narrative review. Postgrad Med 2011; 123(5): 194-204. [PMID: 21904102 DOI: 10.3810/pgm.2011.09.2475]

[50] Lis Y, Roberts MH, Kamble S, Guo JJ, Raisch DW. Comparisons of Food and Drug Administration and European Medicines Agency risk management implementation for recent pharmaceutical approvals: report of the International Society for Pharmacoeconomics and outcomes research risk benefit management working group. Value Health 2012; 15(8): 1108-18. [PMID: 23244814 DOI: 10.1016/j.jval.2012.06.019]

[51] Davis C, Naci H, Gurpinar E, Poplavska E, Pinto A, et al. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. BMJ 2017; 359: j4530. [PMID: 28978555 DOI: 10.1136/bmj.j4530]

[52] Hatswell AJ, Baio G, Berlin JA, Irs A, Freemantle N. Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999-2014. BMJ Open 2016; 6(6): e011666. [PMID: 27363818 DOI: 10.1136/bmjopen-2016-011666]

[53] Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm Res 2016; 33(10): 2373-87. [PMID: 27299311 DOI: 10.1007/s11095-016-1958-5]

[54] Van Norman GA. Drugs, devices, and the FDA: part 1: an overview of approval processes for drugs. JACC Basic Transl Sci 2016; 1(3): 170-9. [PMID: 30167510 DOI: 10.1016/j.jacbts.2016.03.002]

[55] Topol EJ. Failing the public health-rofecoxib, Merck, and the FDA. N Engl J Med 2004; 351(17): 1707-9. [PMID: 15470193 DOI: 10.1056/NEJMp048286]

[56] Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344(11): 783-92. [PMID: 11248153 DOI: 10.1056/NEJM200103153441101]

[57] Zhang X, Zhang Y, Ye X, Guo X, Zhang T, et al. Overview of phase IV clinical trials for postmarket drug safety surveillance: a status report from the ClinicalTrials.gov registry. BMJ Open 2016; 6(11): e010643. [PMID: 27881517 DOI: 10.1136/bmjopen-2015-010643]

[58] Barrett JS. Phase 4, special populations and post-marketing. In: Fundamentals of drug development. John Wiley & Sons, Inc.; 2022. pp. 199.

[59] Le Flohic E, Vrijens B, Hiligsmann M. The impacts of undetected nonadherence in phase II, III and post-marketing clinical trials: an overview. Br J Clin Pharmacol 2024; 90(8): 1984-2003. [PMID: 38752447 DOI: 10.1111/bcp.16089]

[60] Chakraborty A, Venkatraman JV. Pharmacovigilance through phased clinical trials, post-marketing surveillance and ongoing life cycle safety. In: Jagadeesh G, Balakumar P, Senatore F, editors. The quintessence of basic and clinical research and scientific publishing. Singapore: Springer; 2023. pp. 427-42. [DOI: 10.1007/978-981-99-1284-1_27]

[61] Alomar M, Tawfiq AM, Hassan N, Palaian S. Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future. Ther Adv Drug Saf 2020; 11: 2042098620938595. [PMID: 32843958 DOI: 10.1177/2042098620938595]

[62] Berry DA. Bayesian clinical trials. Nat Rev Drug Discov 2006; 5(1): 27-36. [PMID: 16485344 DOI: 10.1038/nrd1927]

[63] Zhou Y, Wang J, Gu Z, Wang S, Zhu W, et al. Next generation of fluorine-containing pharmaceuticals, compounds currently in phase II-III clinical trials of major pharmaceutical companies: new structural trends and therapeutic areas. Chem Rev 2016; 116(2): 422-518. [PMID: 26756377 DOI: 10.1021/acs.chemrev.5b00392]

[64] Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, et al. Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2-assessing respondent understanding. Value Health 2011; 14(8): 978-88. [PMID: 22152166 DOI: 10.1016/j.jval.2011.06.013]

[65] Meyer RE, Salzman C, Youngstrom EA, Clayton PJ, Goodwin FK, et al. Suicidality and risk of suicide-definition, drug safety concerns, and a necessary target for drug development: a brief report. J Clin Psychiatry 2010; 71(8): e1-21. [PMID: 20797373 DOI: 10.4088/JCP.10cs06070blu]

[66] Pallmann P, Bedding AW, Choodari-Oskooei B, Dimairo M, Flight L, et al. Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Med 2018; 16(1): 29. [PMID: 29490655 DOI: 10.1186/s12916-018-1017-7]

[67] Park JJH, Siden E, Zoratti MJ, Dron L, Harari O, et al. Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. Trials 2019; 20(1): 572. [PMID: 31533793 DOI: 10.1186/s13063-019-3664-1]

[68] Fogel DB. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review. Contemp Clin Trials Commun 2018; 11: 156-64. [PMID: 30112460 DOI: 10.1016/j.conctc.2018.08.001]

[69] Getz KA, Campo RA. Trial watch: trends in clinical trial design complexity. Nat Rev Drug Discov 2017; 16(5): 307. [PMID: 28417986 DOI: 10.1038/nrd.2017.65]

[70] Fouka G, Mantzorou M. What are the major ethical issues in conducting research? Is there a conflict between the research ethics and the nature of nursing? Health Sci J 2011; 5(1): 3-14.

[71] Sieber JE, Tolich MB. Planning ethically responsible research. Sage Publications; 2012. vol. 31. pp. 238.

[72] Harris J. Scientific research is a moral duty. J Med Ethics 2005; 31(4): 242-8. [PMID: 15800367 DOI: 10.1136/jme.2005.011973]

[73] Pramesh CS, Badwe RA, Bhoo-Pathy N, Booth CM, Chinnaswamy G, et al. Priorities for cancer research in low- and middle-income countries: a global perspective. Nat Med 2022; 28(4): 649-57. [PMID: 35440716 DOI: 10.1038/s41591-022-01738-x]

[74] Aluwihare-Samaranayake D. Ethics in qualitative research: a view of the participants’ and researchers’ world from a critical standpoint. Int J Qual Methods 2012; 11(2): 64-81. [DOI: 10.1177/160940691201100208]

[75] Yegros-Yegros A, Van de Klippe W, Abad-Garcia MF, Rafols I. Exploring why global health needs are unmet by research efforts: the potential influences of geography, industry and publication incentives. Health Res Policy Syst 2020; 18(1): 47. [PMID: 32414373 DOI: 10.1186/s12961-020-00560-6]

[76] Levine RJ. Ethics and regulation of clinical research. Yale University Press; 1988.

[77] Swanson GM, Ward AJ. Recruiting minorities into clinical trials toward a participant-friendly system. J Natl Cancer Inst 1995; 87(23): 1747-59. [PMID: 7473831 DOI: 10.1093/jnci/87.23.1747]

[78] Patel MX, Doku V, Tennakoon L. Challenges in recruitment of research participants. Adv Psychiatr Treat 2003; 9(3): 229-38. [DOI: 10.1192/apt.9.3.229]

[79] Ford JG, Howerton MW, Lai GY, Gary TL, Bolen S, et al. Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer 2008; 112(2): 228-42. [PMID: 18008363 DOI: 10.1002/cncr.23157]

[80] Rezaie J, Feghhi M, Etemadi T. A review on exosomes application in clinical trials: perspective, questions, and challenges. Cell Commun Signal 2022; 20(1): 145. [PMID: 36123730 DOI: 10.1186/s12964-022-00959-4]

[81] Piller I, Zhang J, Li J. Linguistic diversity in a time of crisis: language challenges of the COVID-19 pandemic. Multilingua 2020; 39(5): 503-15. [DOI: 10.1515/multi-2020-0136]

[82] Turner BE, Steinberg JR, Weeks BT, Rodriguez F, Cullen MR. Race/ethnicity reporting and representation in US clinical trials: a cohort study. Lancet Reg Health Am 2022; 11: 100252. [PMID: 35875251 DOI: 10.1016/j.lana.2022.100252]

[83] U S Food and Drug Administration . Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies: Guidance for Industry; 2024. Docket No. FDA-2024-D-1506. Draft Guidance. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/diversity-action-plans-improve-enrollment-participants-underrepresented-populations-clinical-studies. Published April 2024.

[84] Rabbitt P. How old and young subjects monitor and control responses for accuracy and speed. Br J Psychol 1979; 70(2): 305-11. [DOI: 10.1111/j.2044-8295.1979.tb01687.x]

[85] Yeh AB, Huwang L, Li YM. Profile monitoring for a binary response. IIE Trans 2009; 41(11): 931- 41. [DOI: 10.1080/07408170902735400]

[86] Kazdin AE. Reactive self-monitoring: the effects of response desirability, goal setting, and feedback. J Consult Clin Psychol 1974; 42(5): 704-16. [PMID: 4427011 DOI: 10.1037/h0037050]

[87] Wallach JD, Gonsalves GS, Ross JS. Research, regulatory, and clinical decision-making: the importance of scientific integrity. J Clin Epidemiol 2018; 93: 88-93. [PMID: 29042327 DOI: 10.1016/j.jclinepi.2017.08.021]

[88] Landray MJ, Grandinetti C, Kramer JM, Morrison BW, Ball L, et al. Clinical trials: rethinking how we ensure quality. Drug Inf J 2012; 46(6): 657-60. [DOI: 10.1177/009286151246437]

[89] Prasanna B, Kothapalli P, Vasanthan M. The role of quality assurance in clinical trials: safeguarding data integrity and compliance. Cureus 2024; 16(8): e67573. [PMID: 39310551 DOI: 10.7759/cureus.67573]

[90] Zou W, Zhang R, Schüler E, Taylor PA, Mascia AE, et al. Framework for quality assurance of ultrahigh dose rate clinical trials investigating FLASH effects and current technology gaps. Int J Radiat Oncol Biol Phys 2023; 116(5): 1202-17. [PMID: 37121362 DOI: 10.1016/j.ijrobp.2023.04.018]

[91] Taylor PA, Miles E, Hoffmann L, Kelly SM, Kry SF, et al. Prioritizing clinical trial quality assurance for photons and protons: a failure modes and effects analysis (FMEA) comparison. Radiother Oncol 2023; 182: 109494. [PMID: 36708923 DOI: 10.1016/j.radonc.2023.109494]

[92] Swift B, Jain L, White C, Chandrasekaran V, Bhandari A, et al. Innovation at the intersection of clinical trials and real-world data science to advance patient care. Clin Transl Sci 2018; 11(5): 450-60. [PMID: 29768712 DOI: 10.1111/cts.12559]

[93] Goulooze SC, Zwep LB, Vogt JE, Krekels EHJ, Hankemeier T, et al. Beyond the randomized clinical trial: innovative data science to close the pediatric evidence gap. Clin Pharmacol Ther 2020; 107(4): 786-95. [PMID: 31863465 DOI: 10.1002/cpt.1744]

[94] Inan OT, Tenaerts P, Prindiville SA, Reynolds HR, Dizon D, et al. Digitizing clinical trials. NPJ Digit Med 2020; 3(1): 101. [PMID: 32821856 DOI: 10.1038/s41746-020-0302-y]

[95] Fröhlich H, Balling R, Beerenwinkel N, Kohlbacher O, Kumar S, et al. From hype to reality: data science enabling personalized medicine. BMC Med 2018; 16(1): 150. [PMID: 30145981 DOI: 10.1186/s12916-018-1122-7]

[96] U.S. Food and Drug Administration . Framework for FDA’s real-world evidence program; 2018. Available from: https://www.fda.gov/media/120060/download.

[97] Askin S, Burkhalter D, Calado G, El Dakrouni S. Artificial intelligence applied to clinical trials: opportunities and challenges. Health Technol (Berl) 2023; 13(2): 203- 13. [PMID: 36923325 DOI: 10.1007/s12553-023-00738-2]

[98] Ruksakulpiwat S, Kumar A, Ajibade A. Using ChatGPT in medical research: current status and future directions. J Multidiscip Healthc 2023; 16: 1513-20. [PMID: 37274428 DOI: 10.2147/JMDH.S413470]

[99] Gomase VS, Sharma R, Sardana S. Emerging technology of pharmaceutical compliance: role of automation tools in regulatory affairs for clinical trials. Rev Recent Clin Trials 2025. [PMID: 40849754 DOI: 10.2174/0115748871366461250802092217]

[100] Joshi G, Jain A, Araveeti SR, Adhikari S, Garg H, et al. FDA-approved artificial intelligence and machine learning (AI/ML)-enabled medical devices: an updated landscape. Electronics 2024; 13(3): 498. [DOI: 10.3390/electronics13030498]

[101] Singh S, Kumar R, Payra S, Singh SK. Artificial intelligence and machine learning in pharmacological research: bridging the gap between data and drug discovery. Cureus 2023; 15(8): e44359. [PMID: 37779744 DOI: 10.7759/cureus.44359]

[102] Tiwari PC, Pal R, Chaudhary MJ, Nath R. Artificial intelligence revolutionizing drug development: exploring opportunities and challenges. Drug Dev Res 2023; 84(8): 1652-63. [PMID: 37712494 DOI: 10.1002/ddr.22115]

[103] Gomase VS, Ghatule AP, Sharma R, Sardana S. Leveraging artificial intelligence for data integrity, transparency, and security in technology-enabled improvements to clinical trial data management in healthcare. Rev Recent Clin Trials 2025. [PMID: 40873273 DOI: 10.2174/0115748871371119250818102753]

[104] González-González CS, Muñoz-Cruz V, Toledo-Delgado PA, Nacimiento-García E. Personalized gamification for learning: a reactive chatbot architecture proposal. Sensors (Basel) 2023; 23(1): 545. [PMID: 36617143 DOI: 10.3390/s23010545]

[105] Sherani AMK, Khan M, Qayyum MU, Hussain HK. Synergizing AI and healthcare: pioneering advances in cancer medicine for personalized treatment. Int J Multidiscip SciArts 2024; 3(2): 270-7. [DOI: 10.47709/ijmdsa.v3i01.3562]

[106] Chen J, Yi C, Okegbile SD, Cai J, Shen X. Networking architecture and key supporting technologies for human digital twin in personalized healthcare: a comprehensive survey. IEEE Commun Surv Tutor 2023; 26(1): 706-46. [DOI: 10.1109/COMST.2023.3308717]

[107] Vora LK, Gholap AD, Jetha K, Thakur RRS, Solanki HK, et al. Artificial intelligence in pharmaceutical technology and drug delivery design. Pharmaceutics 2023; 15(7): 1916. [PMID: 37514102 DOI: 10.3390/pharmaceutics15071916]

[108] Fountzilas E, Tsimberidou AM, Vo HH, Kurzrock R. Clinical trial design in the era of precision medicine. Genome Med 2022; 14(1): 101. [PMID: 36045401 DOI: 10.1186/s13073-022-01102-1]

[109] Al-Worafi YM. Technology for drug safety: current status and future developments. Cham: Springer; 2023. [DOI: 10.1007/978-3-031-34268-4]

[110] Salinari A, Machì M, Armas Diaz Y, Cianciosi D, Qi Z, et al. The application of digital technologies and artificial intelligence in healthcare: an overview on nutrition assessment. Diseases 2023; 11(3): 97. [PMID: 37489449 DOI: 10.3390/diseases11030097]

[111] Feigin VL, Owolabi M, Hankey GJ, Pandian J, Martins SC. Digital health in primordial and primary stroke prevention: a systematic review. Stroke 2022; 53(3): 1008-19. [PMID: 35109683 DOI: 10.1161/STROKEAHA.121.036400]

[112] Urbaniak A, Thummel KE, Alade AN, Rettie AE, Prasad B, et al. Experimental pharmacology in precision medicine. Pharmacol Res Perspect 2023; 11(6): e01147. [PMID: 37885364 DOI: 10.1002/prp2.1147]

[113] Marques L, Costa B, Pereira M, Silva A, Santos J, et al. Advancing precision medicine: a review of innovative in silico approaches for drug development, clinical pharmacology and personalized healthcare. Pharmaceutics 2024; 16(3): 332. [PMID: 38543226 DOI: 10.3390/pharmaceutics16030332]

[114] Fu S, Gerber DE, Beg MS. Decentralized clinical trials in oncology: are we ready for a virtual-first paradigm? J Clin Oncol 2022; 41(2): 181-5. [PMID: 35994691 DOI: 10.1200/JCO.22.00358]

[115] Nomali M, Mehrdad N, Heidari ME, Ayati A, Yadegar A, et al. Challenges and solutions in clinical research during the COVID-19 pandemic: a narrative review. Health Sci Rep 2023; 6(8): e1482. [PMID: 37554954 DOI: 10.1002/hsr2.1482]

[116] Mittermaier M, Venkatesh KP, Kvedar JC. Digital health technology in clinical trials. NPJ Digit Med 2023; 6(1): 88. [PMID: 37202443 DOI: 10.1038/s41746-023-00841-8]

[117] DiMasi JA, Smith Z, Oakley-Girvan I, Mackinnon A, Costello M, et al. Assessing the financial value of decentralized clinical trials. Ther Innov Regul Sci 2023; 57(2): 209-19.

[118] Bertsimas D, Kallus N. The power and limits of predictive approaches to observational data-driven optimization: the case of pricing. INFORMS J Optim 2023; 5(1): 110-29. [DOI: 10.1287/ijoo.2022.0077]

[119] Xu L, Wu F, Chen R, Li L. Data-driven-aided strategies in battery lifecycle management: prediction, monitoring, and optimization. Energy Storage Mater 2023; 59: 102785. [DOI: 10.1016/j.ensm.2023.102785]

[120] Wang H, Guan L, Deng M. Recent progress of the genetics of amyotrophic lateral sclerosis and challenges of gene therapy. Front Neurosci 2023; 17: 1170996. [PMID: 37250416 DOI: 10.3389/fnins.2023.1170996]

[121] Lek A, Atas E, Hesterlee SE, Byrne BJ, Bönnemann CG . Meeting report: 2022 muscular dystrophy association summit on ‘safety and challenges in gene transfer therapy’. J Neuromuscul Dis 2023; 10(3): 327-36. [PMID: 36806515 DOI: 10.3233/JND-221639]

[122] Zabaleta N, Unzu C, Weber ND, Gonzalez-Aseguinolaza G. Gene therapy for liver diseases - progress and challenges. Nat Rev Gastroenterol Hepatol 2023; 20(5): 288-305. [PMID: 36646909 DOI: 10.1038/s41575-022-00729-0]

[123] Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet 2017; 390(10097): 849-60. [PMID: 28712537 DOI: 10.1016/S0140-6736(17)31868-8]

[124] Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 2017; 377(18): 1713-22. [PMID: 29091557 DOI: 10.1056/NEJMoa1706198]

[125] Ghorani E, Quartagno M, Blackhall F, Gilbert DC, O’Brien M, et al. REFINE-Lung implements a novel multi-arm randomised trial design to address possible immunotherapy overtreatment. Lancet Oncol 2023; 24(5): e219-27. [PMID: 37142383 DOI: 10.1016/S1470-2045(23)00095-5]

[126] Kamat AM, Apolo AB, Babjuk M, Bivalacqua TJ, Black PC, et al. Definitions, end points, and clinical trial designs for bladder cancer: recommendations from the Society for Immunotherapy of Cancer and the International Bladder Cancer Group. J Clin Oncol 2023; 41(35): 5437-47. [PMID: 37793077 DOI: 10.1200/JCO.23.00307]

[127] Creemers JHA, Ankan A, Roes KCB, Schröder G, Mehra N, et al. In silico cancer immunotherapy trials uncover the consequences of therapy-specific response patterns for clinical trial design and outcome. Nat Commun 2023; 14(1): 2348. [PMID: 37095077 DOI: 10.1038/s41467-023-37933-8]

[128] Marcus L, Fashoyin-Aje LA, Donoghue M, Yuan M, Rodriguez L, et al. FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors. Clin Cancer Res 2021; 27(17): 4685-9. [PMID: 34083238 DOI: 10.1158/1078-0432.CCR-21-0327]

[129] Pansara R. Unraveling the complexities of data governance with strategies, challenges, and future directions. Transact Latest Trends IoT 2023; 6(6): 46-56.

[130] Abrahams TO, Ewuga SK, Kaggwa S, Uwaoma PU, Hassan AO, et al. Mastering compliance: a comprehensive review of regulatory frameworks in accounting and cybersecurity. Comput Sci IT Res J 2024; 5(1): 120-40. [DOI: 10.51594/csitrj.v5i1.709]

[131] Apeh AJ, Hassan AO, Oyewole OO, Fakeyede OG, Okeleke PA, et al. GRC strategies in modern cloud infrastructures: a review of compliance challenges. Comput Sci IT Res J 2023; 4(2): 111-25. [DOI: 10.51594/csitrj.v4i2.609]

[132] Gomase VS, Sharma R, Dhamane SP. Global analysis of regulatory frameworks and drug safety standards in the drug approval process. Curr Drug Saf 2025. [PMID: 40916422 DOI: 10.2174/0115748863392869250827042742]

[133] Collij LE, Farrar G, Valléz García D, Bader I, Shekari M, et al. The amyloid imaging for the prevention of Alzheimer’s disease consortium: a European collaboration with global impact. Front Neurol 2023; 13: 1063598. [PMID: 36761917 DOI: 10.3389/fneur.2022.1063598]

[134] Teske AJ, Moudgil R, López-Fernández T, Barac A, Brown SA, et al. Global Cardio Oncology Registry (G-COR): registry design, primary objectives, and future perspectives of a multicenter global initiative. Circ Cardiovasc Qual Outcomes 2023; 16(10): e009905 [PMID: 37702048 DOI: 10.1161/CIRCOUTCOMES.123.009905]

[135] Llibre-Guerra JJ, Heavener A, Brucki SMD, Marante JPD, Pintado-Caipa M, et al. A call for clinical trial globalization in Alzheimer’s disease and related dementia. Alzheimers Dement 2023; 19(7): 3210-21. [PMID: 36840622 DOI: 10.1002/alz.12995]